Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries

International Journal of Cardiology

Volumn 205, Issue , 2016, Pages 147-156

  Webster, Ruth ^a   Patel, Anushka ^a   Selak, Vanessa ^b   Billot, Laurent ^a   Bots, Michiel L ^c   Brown, Alex ^d   Bullen, Chris ^b   Cass, Alan ^e   Crengle, Sue ^f   Raina Elley, C ^b   Grobbee, Diederick E ^c   Neal, Bruce ^a   Peiris, David ^a   Poulter, Neil ^g   Prabhakaran, Dorairaj ^h   Rafter, Natasha ^b   Stanton, Alice ⁱ   Stepien, Sandrine ^a   Thom, Simon ^g   Usherwood, Tim ^j   Wadham, Angela ^b   Rodgers, Anthony ^a   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^f Invercargill Medical Centre   (New Zealand)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h Department of Radiation Oncology   (India)

ⁱ ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^j UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

Cardiovascular disease; Meta analysis; Polypill; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; AUSTRALIA; BREAST DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONNECTIVE TISSUE DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HIGH RISK PATIENT; HUMAN; INDIA; INFECTION; INJURY; INNER EAR DISEASE; INTERVENTION STUDY; INTOXICATION; IRELAND; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; NEOPLASM; NETHERLANDS; NEUROLOGIC DISEASE; NEW ZEALAND; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DRUG COMBINATION; ENGLAND; FACTUAL DATABASE; PROCEDURES; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; AUSTRALIA; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DRUG COMBINATIONS; ENGLAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDIA; IRELAND; NETHERLANDS; NEW ZEALAND; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84955451028     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.12.015     Document Type: Article

References (29)

1. S. Yusuf, S. Islam, C.K. Chow, S. Rangarajan, G. Dagenais, R. Diaz, and et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey Lancet 378 9798 2011 1231 1243
2. M. Lafeber, W. Spiering, K. Singh, R.K. Guggilla, V. Patel, and R. Webster The cardiovascular polypill in high-risk patients Eur. J. Cardiovasc. Prev. Rehabil. 2011
3. World Health Organization Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions (Geneva) 2002
4. A. Patel, A. Cass, D. Peiris, T. Usherwood, A. Brown, S. Jan, and et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk Eur. J. Prev. Cardiol. 2014
5. V. Selak, C.R. Elley, C. Bullen, S. Crengle, A. Wadham, N. Rafter, and et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care BMJ 348 2014
6. S. Thom, N. Poulter, J. Field, A. Patel, D. Prabhakaran, A. Stanton, and et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial JAMA 310 9 2013 918 929
7. J.M. Castellano, G. Sanz, J.L. Penalvo, S. Bansilal, A. Fernandez-Ortiz, L. Alvarez, and et al. A polypill strategy to improve adherence: results from FOCUS (Fixed-dose combination drug for secondary cardiovascular prevention) project J. Am. Coll. Cardiol. 2014
8. R. Webster, A. Patel, L. Billot, A. Cass, C. Burch, B. Neal, and et al. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE collaboration Int. J. Cardiol. 170 1 2013 30 35
9. H.M. Liu, A. Patel, A. Brown, S. Eades, N. Hayman, S. Jan, and et al. Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non-indigenous people at high cardiovascular risk BMC Public Health 10 2010 458
10. V. Selak, C.R. Elley, S. Crengle, M. Harwood, R. Doughty, B. Arroll, and et al. Improving adherence using combination therapy (IMPACT): design and protocol of a randomised controlled trial in primary care Contemp. Clin. Trials 32 6 2011 909 915
11. S. Thom, J. Field, N. Poulter, A. Patel, D. Prabhakaran, A. Stanton, and et al. Use of a multidrug pill in reducing cardiovascular events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe Eur. J. Prev. Cardiol. 2012
12. New Zealand Guidelines Group New Zealand Cardiovascular Guidelines Handbook: a Summary Resource for Primary Care Practitioners 2005 New Zealand Guidelines Group Wellington
13. World Health Organisation Adherence to Long-term Therapies. Evidence for Action 2003 WHO Geneva
14. T.P.A. Debray, K.G.M. Moons, G.M.A. Abo-Zaid, H. Koffijberg, and R.D. Riley Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? PLoS ONE 8 4 2013 e60650
15. C.P. Cannon Can the polypill save the world from heart disease? Lancet 373 9672 2009 1313 1314
16. M. Helfand, S. Carson, and C. Kelley Drug Class Review on HMG-CoA Reductase Inhibitors (Statins): Final Report 2006 Oregon Health & Science University Portland (OR)
17. http://www.meddra.org/ (accessed 3rd September 2014)
18. Pill Collaborative Group A. Rodgers, A. Patel, O. Berwanger, M. Bots, R. Grimm, and et al. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk PLoS ONE 6 5 2011 e19857
19. R. Collins, R. Peto, S. MacMahon, P. Hebert, N.H. Fiebach, K.A. Eberlein, and et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context [see comment] Lancet 335 8693 1990 827 838
20. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, and et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 9493 2005 1267 1278
21. M.R. Law, J.K. Morris, and N.J. Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 2009 b1665
22. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients Br. Med. J. 308 6921 1994 81 106
23. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
24. E. Soliman, S. Mendis, W. Dissanayake, N. Somasundaram, P. Gunaratne, I.K. Jayasingne, and et al. A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization Trials 12 1 2011 3
25. S. Yusuf, P. Pais, A. Sigamani, D. Xavier, R. Afzal, P. Gao, and et al. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the second Indian polycap study (TIPS-2) investigators Circ. Cardiovasc. Qual. Outcomes 5 4 2012 463 471
26. C.R. Elley, A.K. Gupta, R. Webster, V. Selak, M. Jun, A. Patel, and et al. The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials PLoS ONE 7 12 2012 e52145-e
27. A.N. de Cates, M.R. Farr, N. Wright, M.C. Jarvis, K. Rees, S. Ebrahim, and et al. Fixed-dose combination therapy for the prevention of cardiovascular disease Cochrane Database Syst. Rev. 4 2014 CD009868
28. S. Yusuf, S. Islam, C.K. Chow, S. Rangarajan, G. Dagenais, R. Diaz, and et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey Lancet 378 2011 1231 1243
29. World Health Organisation Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013 World Health Organization Geneva